Literature DB >> 20471507

Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice.

Manshan Xu1, Shilpa Choudhary, Olga Voznesensky, Qi Gao, Douglas Adams, Vilmaris Diaz-Doran, Qian Wu, David Goltzman, Lawrence G Raisz, Carol C Pilbeam.   

Abstract

Cyclooxygenase-2 (COX-2) knockout (KO) mice in inbred strains can have renal dysfunction with secondary hyperparathyroidism (HPTH), making direct effects of COX-2 KO on bone difficult to assess. COX-2 KO mice in an outbred CD-1 background did not have renal dysfunction but still had two-fold elevated PTH compared to wild type (WT) mice. Compared to WT mice, KO mice had increased serum markers of bone turnover, decreased femoral bone mineral density (BMD) and cortical bone thickness, but no differences in trabecular bone volume by microCT or dynamic histomorphometry. Because PTH is a potent inducer of COX-2 and prostaglandin (PG) production, we examined the effects of COX-2 KO on bone responses after 3 weeks of intermittent PTH. Intermittent PTH increased femoral BMD and cortical bone area more in KO mice than in WT mice and increased trabecular bone volume in the distal femur in both WT and KO mice. Although not statistically significant, PTH-stimulated increases in trabecular bone tended to be greater in KO mice than in WT mice. PTH increased serum markers of bone formation and resorption more in KO than in WT mice but increased the ratio of osteoblastic surface-to-osteoclastic surface only in KO mice. PTH also increased femoral mineral apposition rates and bone formation rates in KO mice more than in WT mice. Acute mRNA responses to PTH of genes that might mediate some anabolic and catabolic effects of PTH tended to be greater in KO than WT mice. We conclude that (1) the basal bone phenotype in male COX-2 KO mice might reflect HPTH, COX-2 deficiency or both, and (2) increased responses to intermittent PTH in COX-2 KO mice, despite the presence of chronic HPTH, suggest that absence of COX-2 increased sensitivity to PTH. It is possible that manipulation of endogenous PGs could have important clinical implications for anabolic therapy with PTH. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471507      PMCID: PMC3056501          DOI: 10.1016/j.bone.2010.05.006

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  71 in total

1.  Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. Reversibility of effects after short-term treatment.

Authors:  L C Gerstenfeld; M Al-Ghawas; Y M Alkhiary; D M Cullinane; E A Krall; J L Fitch; E G Webb; M A Thiede; T A Einhorn
Journal:  J Bone Joint Surg Am       Date:  2007-01       Impact factor: 5.284

2.  The isozyme-specific effects of cyclooxygenase-deficiency on bone in mice.

Authors:  L K Myers; S D Bhattacharya; P A Herring; Z Xing; S Goorha; R A Smith; S K Bhattacharya; L Carbone; Roberta Faccio; A H Kang; L R Ballou
Journal:  Bone       Date:  2006-07-27       Impact factor: 4.398

3.  Prostaglandin E2 stimulates the formation of mineralized bone nodules by a cAMP-independent mechanism in the culture of adult rat calvarial osteoblasts.

Authors:  H Kaneki; I Takasugi; M Fujieda; M Kiriu; S Mizuochi; H Ide
Journal:  J Cell Biochem       Date:  1999-04-01       Impact factor: 4.429

4.  Downregulation of SOST/sclerostin by PTH: a novel mechanism of hormonal control of bone formation mediated by osteocytes.

Authors:  T Bellido
Journal:  J Musculoskelet Neuronal Interact       Date:  2006 Oct-Dec       Impact factor: 2.041

5.  Proto-oncogene c-fos is transcriptionally regulated by parathyroid hormone (PTH) and PTH-related protein in a cyclic adenosine monophosphate-dependent manner in osteoblastic cells.

Authors:  L K McCauley; A J Koh; C A Beecher; T J Rosol
Journal:  Endocrinology       Date:  1997-12       Impact factor: 4.736

6.  Differential effects of systemic prostaglandin E2 on bone mass in rat long bones and calvariae.

Authors:  I Suponitzky; M Weinreb
Journal:  J Endocrinol       Date:  1998-01       Impact factor: 4.286

7.  SOST is a target gene for PTH in bone.

Authors:  Hansjoerg Keller; Michaela Kneissel
Journal:  Bone       Date:  2005-08       Impact factor: 4.398

8.  Do cyclooxygenase-2 knockout mice have primary hyperparathyroidism?

Authors:  Manshan Xu; Shilpa Choudhary; David Goltzman; Felicia Ledgard; Douglas Adams; Gloria Gronowicz; Boguslawa Koczon-Jaremko; Lawrence Raisz; Carol Pilbeam
Journal:  Endocrinology       Date:  2004-12-29       Impact factor: 4.736

9.  Mechanotransduction in bone does not require a functional cyclooxygenase-2 (COX-2) gene.

Authors:  Imranul Alam; Stuart J Warden; Alexander G Robling; Charles H Turner
Journal:  J Bone Miner Res       Date:  2004-11-29       Impact factor: 6.741

10.  Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone.

Authors:  K Tsukii; N Shima; S Mochizuki; K Yamaguchi; M Kinosaki; K Yano; O Shibata; N Udagawa; H Yasuda; T Suda; K Higashio
Journal:  Biochem Biophys Res Commun       Date:  1998-05-19       Impact factor: 3.575

View more
  10 in total

1.  Hyperlipidemia induces resistance to PTH bone anabolism in mice via oxidized lipids.

Authors:  Andrew P Sage; Jinxiu Lu; Elisa Atti; Sotirios Tetradis; Maria-Grazia Ascenzi; Douglas J Adams; Linda L Demer; Yin Tintut
Journal:  J Bone Miner Res       Date:  2011-06       Impact factor: 6.741

2.  Prostaglandin-mediated inhibition of PTH-stimulated β-catenin signaling in osteoblasts by bone marrow macrophages.

Authors:  Thomas L Estus; Shilpa Choudhary; Carol C Pilbeam
Journal:  Bone       Date:  2016-02-03       Impact factor: 4.398

3.  Serum Amyloid A3 Secreted by Preosteoclasts Inhibits Parathyroid Hormone-stimulated cAMP Signaling in Murine Osteoblasts.

Authors:  Shilpa Choudhary; Alexandra Goetjen; Thomas Estus; Christian E Jacome-Galarza; Hector L Aguila; Joseph Lorenzo; Carol Pilbeam
Journal:  J Biol Chem       Date:  2015-12-23       Impact factor: 5.157

4.  Cyclooxygenase-2 suppresses the anabolic response to PTH infusion in mice.

Authors:  Shilpa Choudhary; Ernesto Canalis; Thomas Estus; Douglas Adams; Carol Pilbeam
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

5.  Fibroblast Growth Factor Receptor 3 Deficiency Does Not Impair the Osteoanabolic Action of Parathyroid Hormone on Mice.

Authors:  Yangli Xie; Lingxian Yi; Tujun Weng; Junlan Huang; Fengtao Luo; Wanling Jiang; Cory J Xian; Xiaolan Du; Lin Chen
Journal:  Int J Biol Sci       Date:  2016-07-17       Impact factor: 6.580

6.  The Osteogenesis Imperfecta Type V Mutant BRIL/IFITM5 Promotes Transcriptional Activation of MEF2, NFATc, and NR4A in Osteoblasts.

Authors:  Vincent Maranda; Marie-Hélène Gaumond; Pierre Moffatt
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

Review 7.  NSAID therapy effects on healing of bone, tendon, and the enthesis.

Authors:  Bailey Su; J Patrick O'Connor
Journal:  J Appl Physiol (1985)       Date:  2013-07-18

8.  Prostaglandin E2 acts via bone marrow macrophages to block PTH-stimulated osteoblast differentiation in vitro.

Authors:  Shilpa Choudhary; Katherine Blackwell; Olga Voznesensky; Abhijit Deb Roy; Carol Pilbeam
Journal:  Bone       Date:  2013-04-29       Impact factor: 4.398

9.  Pyrroloquinoline Quinone Prevents Estrogen Deficiency-Induced Osteoporosis by Inhibiting Oxidative Stress and Osteocyte Senescence.

Authors:  Qinghe Geng; Haiyan Gao; Renlei Yang; Kaijin Guo; Dengshun Miao
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

10.  Anabolic actions of PTH in murine models: two decades of insights.

Authors:  Laura E Zweifler; Amy J Koh; Stephanie Daignault-Newton; Laurie K McCauley
Journal:  J Bone Miner Res       Date:  2021-07-27       Impact factor: 6.741

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.